{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T21:53:05Z","timestamp":1781992385430,"version":"3.54.5"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:00:00Z","timestamp":1663545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"\nBackground<\/jats:title>\nThe number of biological DMARDs (bDMARDs) used in elderly patients with rheumatoid arthritis (RA) has increased in recent years. We aimed to compare the drug retention rates and safety of abatacept (ABT) and tocilizumab (TCZ) in elderly patients with RA.<\/jats:p>\n<\/jats:sec>\n\nMethods<\/jats:title>\nA total 125 elderly patients with RA (>65 years) who began therapy with either ABT (n = 47) or TCZ (n = 78) between 2014 and 2021 at our institute were enrolled. We compared the drug retention rate and clinical response at 24 weeks between elderly patients with RA treated with ABT and those treated with TCZ. Adverse events (AEs) and the reasons for drug discontinuation were assessed.<\/jats:p>\n<\/jats:sec>\n\nResults<\/jats:title>\nThere was no significant difference in demographic characteristics except for the use of glucocorticoid between the ABT and TCZ groups. There was no significant difference in the drug retention rate between the ABT and TCZ groups. Furthermore, there was no significant difference in the discontinuation rates due to the lack of effectiveness between these two groups. The proportions of the patients archiving low disease activity at 24 weeks did not differ significantly between the two groups. Whereas, the discontinuation rates due to AEs, including interstitial lung disease (ILD), seemed higher in the TCZ group than in the ABT group. In TCZ-treated group, the concomitant use of methotrexate (MTX) significantly increased the incidences of AEs leading to the discontinuation of TCZ. Whereas these was no significant impact of concomitant use of MTX on the incidences of AEs leading to discontinuation in ABT-treated group.<\/jats:p>\n<\/jats:sec>\n\nConclusions<\/jats:title>\nIn elderly patients with RA treated with ABT and TCZ, drug retention rates were equivalent between the two groups. There were some differences in safety profiles between ABT and TCZ, and the rates of discontinuation due to AEs, including ILD, seem to be lower with ABT than with TCZ in elderly patients with RA.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0274775","type":"journal-article","created":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T17:34:06Z","timestamp":1663608846000},"page":"e0274775","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comparing the effectiveness and safety of Abatacept and Tocilizumab in elderly patients with rheumatoid arthritis"],"prefix":"10.1371","volume":"17","author":[{"given":"Jumpei","family":"Temmoku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Sumichika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuzo","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1339-5622","authenticated-orcid":true,"given":"Kiyoshi","family":"Migita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,9,19]]},"reference":[{"issue":"7","key":"pone.0274775.ref001","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/1756-185X.12998","article-title":"The age at onset of rheumatoid arthritis is increasing in Japan: a nationwide database study.","volume":"20","author":"E Kato","year":"2017","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"pone.0274775.ref002","doi-asserted-by":"crossref","first-page":"102528","DOI":"10.1016\/j.autrev.2020.102528","article-title":"Rheumatoid arthritis in the elderly: Characteristics and treatment considerations.","volume":"19","author":"L Serhal","year":"2020","journal-title":"Autoimmun Rev."},{"issue":"10","key":"pone.0274775.ref003","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/nrrheum.2013.92","article-title":"The influence of ageing on the development and management of rheumatoid arthritis","volume":"9","author":"AM Boots","year":"2013","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"pone.0274775.ref004","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41584-022-00768-6","article-title":"Challenges in the management of older patients with inflammatory rheumatic diseases.","volume":"18","author":"M van Onna","year":"2022","journal-title":"Nat Rev Rheumatol."},{"issue":"1","key":"pone.0274775.ref005","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13075-021-02496-w","article-title":"Comparison of the drug retention and reasons for discontinuation of tumor necrosis factor inhibitors and interleukin-6 inhibitors in Japanese patients with elderly-onset rheumatoid arthritis-the ANSWER cohort study.","volume":"23","author":"S Jinno","year":"2021","journal-title":"Arthritis Res Ther."},{"issue":"Suppl 1","key":"pone.0274775.ref006","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/ar2416","article-title":"Abatacept in the treatment of rheumatoid arthritis.","volume":"10","author":"MH Buch","year":"2008","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"pone.0274775.ref007","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/rheumatology\/kev437","article-title":"Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology\u2019s ORA registry.","volume":"55","author":"C Lahaye","year":"2016","journal-title":"Rheumatology (Oxford"},{"issue":"5","key":"pone.0274775.ref008","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/14397595.2018.1524998","article-title":"Safety and effectiveness of abatacept in Japanese non-elderly and elderly patients with rheumatoid arthritis in an all-cases post-marketing surveillance.","volume":"29","author":"M Harigai","year":"2019","journal-title":"Mod Rheumatol."},{"issue":"3","key":"pone.0274775.ref009","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1159\/000164393","article-title":"Proinflammatory cytokine profiles of patients with elderly-onset rheumatoid arthritis: a comparison with younger-onset disease","volume":"55","author":"DY Chen","year":"2009","journal-title":"Gerontology"},{"issue":"9","key":"pone.0274775.ref010","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative.","volume":"62","author":"D Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"5","key":"pone.0274775.ref011","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/acr.21649","article-title":"Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice.","volume":"64","author":"J Anderson","year":"2012","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"4","key":"pone.0274775.ref012","doi-asserted-by":"crossref","first-page":"R796","DOI":"10.1186\/ar1740","article-title":"Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score.","volume":"7","author":"D Aletaha","year":"2005","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"pone.0274775.ref013","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/RHU.0000000000000469","article-title":"The Reliability of Disease Activity Score in 28 Joints-C-Reactive Protein Might Be Overestimated in a Subgroup of Rheumatoid Arthritis Patients, When the Score Is Solely Based on Subjective Parameters: A Cross-sectional, Exploratory Study.","volume":"23","author":"IM Jensen Hansen","year":"2017","journal-title":"J Clin Rheumatol."},{"issue":"4","key":"pone.0274775.ref014","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1136\/annrheumdis-2015-207942","article-title":"Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial","volume":"75","author":"J Sokolove","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"pone.0274775.ref015","doi-asserted-by":"crossref","first-page":"e012812","DOI":"10.1136\/bmjopen-2016-012812","article-title":"Burden of multimorbidity in relation to age, gender and immigrant status: a cross-sectional study based on administrative data","volume":"6","author":"J Lenzi","year":"2016","journal-title":"BMJ Open"},{"issue":"1","key":"pone.0274775.ref016","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/art.37711","article-title":"Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study","volume":"65","author":"ME Weinblatt","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"4","key":"pone.0274775.ref017","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s40744-021-00356-2","article-title":"Abatacept is Efficacious in the Treatment of Older Patients with csDMARD-Refractory Rheumatoid Arthritis: A Prospective, Multicenter, Observational Study.","volume":"8","author":"S Muraoka","year":"2021","journal-title":"Rheumatol Ther."},{"issue":"10","key":"pone.0274775.ref018","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/1756-185X.14194","article-title":"A bond between rheumatic diseases and cancer in the elderly: The interleukin-6 pathway.","volume":"24","author":"GC Iorio","year":"2021","journal-title":"Int J Rheum Dis."},{"key":"pone.0274775.ref019","doi-asserted-by":"crossref","first-page":"102400","DOI":"10.1016\/j.jaut.2019.102400","article-title":"The etiology of rheumatoid arthritis","volume":"110","author":"HU Scherer","year":"2020","journal-title":"J Autoimmun"},{"key":"pone.0274775.ref020","article-title":"The safety and effectiveness of tocilizumab in elderly patients with rheumatoid arthritis and in patients with comorbidities associated with age","author":"C Specker","year":"2021","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"pone.0274775.ref021","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/acr.22640","article-title":"Physician Preferences and Variations in Prescription of Biologic Drugs for Rheumatoid Arthritis: A Register-Based Study of 4,010 Patients in Sweden.","volume":"67","author":"A Kalkan","year":"2015","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"7","key":"pone.0274775.ref022","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/rheumatology\/kez021","article-title":"Retention of tocilizumab with and without methotrexate during maintenance therapy for rheumatoid arthritis: the ACTRA-RI cohort study.","volume":"58","author":"S Mori","year":"2019","journal-title":"Rheumatology (Oxford)."},{"issue":"3","key":"pone.0274775.ref023","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/rheumatology\/keq343","article-title":"Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials.","volume":"50","author":"L Campbell","year":"2011","journal-title":"Rheumatology (Oxford)."},{"key":"pone.0274775.ref024","doi-asserted-by":"crossref","first-page":"931342","DOI":"10.1155\/2011\/931342","article-title":"Interstitial lung disease in rheumatoid arthritis in the era of biologics","volume":"2011","author":"A Picchianti Diamanti","year":"2011","journal-title":"Pulm Med"},{"issue":"5","key":"pone.0274775.ref025","doi-asserted-by":"crossref","first-page":"103056","DOI":"10.1016\/j.autrev.2022.103056","article-title":"Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease","volume":"21","author":"M Akiyama","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"9","key":"pone.0274775.ref026","first-page":"504","article-title":"Systematic review of the impact of drugs on diffuse interstitial lung disease associated with rheumatoid arthritis","volume":"17","author":"C Carrasco Cubero","year":"2021","journal-title":"Reumatol Clin (Engl Ed)."},{"issue":"1","key":"pone.0274775.ref027","doi-asserted-by":"crossref","first-page":"13773","DOI":"10.1038\/s41598-020-70743-2","article-title":"Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study","volume":"10","author":"N Okada","year":"2020","journal-title":"Sci Rep"},{"issue":"12","key":"pone.0274775.ref028","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1093\/rheumatology\/keaa621","article-title":"Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients.","volume":"59","author":"C Fern\u00e1ndez-D\u00edaz","year":"2020","journal-title":"Rheumatology (Oxford)."},{"issue":"6","key":"pone.0274775.ref029","doi-asserted-by":"crossref","first-page":"102830","DOI":"10.1016\/j.autrev.2021.102830","article-title":"Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review","volume":"20","author":"EF Vicente-Rabaneda","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"6","key":"pone.0274775.ref030","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/1756-185X.13428","article-title":"Elderly onset of early rheumatoid arthritis is a risk factor for bone erosions, refractory to treatment: KURAMA cohort.","volume":"22","author":"K Murata","year":"2019","journal-title":"Int J Rheum Dis."},{"issue":"2","key":"pone.0274775.ref031","doi-asserted-by":"crossref","first-page":"R94","DOI":"10.1186\/ar4540","article-title":"Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study.","volume":"16","author":"L Innala","year":"2014","journal-title":"Arthritis Res Ther"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0274775","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T17:34:45Z","timestamp":1663608885000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0274775"}},"subtitle":[],"editor":[{"given":"Masataka","family":"Kuwana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,9,19]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0274775","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,19]]}}}